    [Federal Register Volume 91, Number 58 (Thursday, March 26, 2026)]
    [Notices]
    [Pages 14715-14716]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 2026-05906]

    -----------------------------------------------------------------------

    DEPARTMENT OF JUSTICE

    Antitrust Division

    Notice Pursuant to the National Cooperative Research and
    Production Act of 1993--Biopharmaceutical Manufacturing Preparedness
    Consortium

        Notice is hereby given that, on October 8, 2025, pursuant to
    section 6(a) of the National Cooperative Research and Production Act of
    1993, 15 U.S.C. 4301 et seq. (``the Act''), Biopharmaceutical
    Manufacturing Preparedness Consortium (``BIOMAP-CONSORTIUM'') has filed
    written notifications simultaneously with the Attorney General and the
    Federal Trade Commission disclosing changes in its membership. The
    notifications were filed for the purpose of extending the Act's
    provisions limiting the recovery of antitrust plaintiffs to actual
    damages under specified circumstances. Specifically, AGC Biologics,
    Bothell, WA; Anavatos Bio, Inc., Seattle, WA; Cidara Therapeutics INC,
    San Diego, CA; Crossmhv, L.l.C, Tampa, FL; Defense Operations &
    Execution Solutions INC, W Melbourne, FL; Health Supply US LLC,
    Mooresville, NC; Nanopass Technologies Ltd., Nes Ziona, STATE OF
    ISRAEL; Ommio Health, INC, Woodbridge, CT; UI Pharmaceuticals, Iowa
    City, IA; Axelyf, Inc., Chestnut Hill, MA; BetteRx Compounding Inc.,
    Smithfield, RI; Crossject SA, Dijon, FRENCH REPUBLIC; Lavik Consulting
    LLC, Oakland, MO; Nanotag Biotechnologies Gmbh, Goettingen, FEDERAL
    REPUBLIC OF GERMANY; Quality Assured Artificial Intelligence LLC, Green
    Cove Springs, FL; Award Advisors, Washington, DC; Beckman Research
    Institute of the City of Hope, Duarte, CA; Gemini Therapeutics, San
    Fransisco, CA; Lumacyte, INC, Charlottesville, VA; Modus Operandi,

    [[Page 14716]]

    Inc., Melbourne, FL; Ship Odyssey, Inc., Sevierville, TN; Synergistic
    INC, New Baltimore, MI; Occam Systems Incorporated, Glen Allen, VA;
    Renco Manufacturing Group INC, Colebrook, NH; Revolution
    Biomanufacturing INC, Canton, MA; Sagitta Biotech, Li[egrave]ge,
    KINGDOM OF BELGIUM; Argentum Pharmaceuticals LLC, Aspen, CO; Culmen
    International, LLC, Alexandria, VA; EXCITE PHARMA SERVICES, LLC, Lees
    Summit, MO; Johns Hopkins Center for Health Security, Baltimore, MD;
    KNIGHT GREGORIAN, INC., Vista, CA; Kensington Street Consulting LLC,
    Arlington, VA; Method Made, Montreal, CANADA; Mriglobal, Kansas City,
    MO; N! Biomachines Ltd., Burlington, ON; Safi Biotherapeutics INC,
    Cambridge, MA; Science Systems and Applications, Inc., Lanham, MD; True
    Diagnostics, Inc., Carlsbad, CA; and Zeteo Biomedical LLC, Austin, TX
    have been added as parties to this venture.
        No other changes have been made in either the membership or planned
    activity of the group research project. Membership in this group
    research project remains open, and the BIOMAP-CONSORTIUM intends to
    file additional written notifications disclosing all changes in
    membership.
        On January 5, 2024, the BIOMAP-CONSORTIUM filed its original
    notification pursuant to section 6(a) of the Act. The Department of
    Justice published a notice in the Federal Register pursuant to section
    6(b) of the Act on April 16, 2024 (89 FR 26923).
        The last notification was filed with the Department on July 24,
    2025. A notice was published in the Federal Register pursuant to
    section 6(b) of the Act on January 20, 2026 (91 FR 2369).

    Suzanne Morris,
    Deputy Director Civil Enforcement Operations, Antitrust Division.
    [FR Doc. 2026-05906 Filed 3-25-26; 8:45 am]
    BILLING CODE P